ATE235257T1 - Zusammensetzung für behandlung von maligner tumore und ihre metastase - Google Patents
Zusammensetzung für behandlung von maligner tumore und ihre metastaseInfo
- Publication number
- ATE235257T1 ATE235257T1 AT95940764T AT95940764T ATE235257T1 AT E235257 T1 ATE235257 T1 AT E235257T1 AT 95940764 T AT95940764 T AT 95940764T AT 95940764 T AT95940764 T AT 95940764T AT E235257 T1 ATE235257 T1 AT E235257T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor
- lactose
- cytotoxic
- metastasis
- malignant tumors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/360,352 US5639737A (en) | 1991-11-04 | 1994-12-21 | Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors |
PCT/US1995/015097 WO1996019243A1 (en) | 1994-12-21 | 1995-11-27 | Composition for treatment of malignant tumors and their metastases |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE235257T1 true ATE235257T1 (de) | 2003-04-15 |
Family
ID=23417628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95940764T ATE235257T1 (de) | 1994-12-21 | 1995-11-27 | Zusammensetzung für behandlung von maligner tumore und ihre metastase |
Country Status (8)
Country | Link |
---|---|
US (1) | US5639737A (de) |
EP (1) | EP0797453B1 (de) |
AT (1) | ATE235257T1 (de) |
AU (1) | AU692021B2 (de) |
CA (1) | CA2208206C (de) |
DE (1) | DE69530109T2 (de) |
IL (1) | IL116465A (de) |
WO (1) | WO1996019243A1 (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074643A (en) * | 1993-09-09 | 2000-06-13 | Cli Oncology, Inc. | Site-directed chemotherapy of metastases |
DE19524515A1 (de) * | 1995-07-05 | 1997-01-09 | Deutsches Krebsforsch | Saccharid-Konjugate |
US6391547B1 (en) * | 1997-09-09 | 2002-05-21 | Center For The Application Of Molecular Biology To International Agriculture | Microbial β-glucuronidase genes, gene products and uses thereof |
US7087420B1 (en) | 1997-07-17 | 2006-08-08 | Cambia | Microbial β-glucuronidase genes, gene products and uses thereof |
DK1098641T3 (en) * | 1998-07-27 | 2016-08-15 | St Jude Pharmaceuticals Inc | Chemically induced intracellular hyperthermia |
CA2338638C (en) * | 1998-07-30 | 2009-03-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
ATE431141T1 (de) | 1999-07-13 | 2009-05-15 | Alpha Res Group Llc | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit |
US20040229908A1 (en) * | 1999-07-13 | 2004-11-18 | Jodi Nelson | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias |
US7345031B2 (en) * | 2000-04-12 | 2008-03-18 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
US6548484B1 (en) * | 2000-04-12 | 2003-04-15 | International Medical Innovations, Inc. | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation |
US20060189547A1 (en) * | 2000-04-12 | 2006-08-24 | Christian Samuel T | Novel pharmaceutical agents containing carbohydrate moieties and methods of their preparation and use |
US9302982B2 (en) | 2000-04-12 | 2016-04-05 | Glycon Llc | Pharmaceutical dopamine glycoconjugate compositions and methods of their preparation and use |
WO2002026262A2 (en) * | 2000-09-25 | 2002-04-04 | Pro-Pharmaceuticals, Inc. | Compositions for reducing side effects in chemotherapeutic treatments |
CN100516059C (zh) * | 2001-04-10 | 2009-07-22 | 宝生物工程株式会社 | 治疗剂 |
US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
US20040058865A1 (en) * | 2001-11-26 | 2004-03-25 | Danishefsky Samuel J | Homing peptide multimers, their preparation and uses |
US6916627B2 (en) * | 2002-11-27 | 2005-07-12 | St. Jude Children's Research Hospital | ATM kinase compositions and methods |
US20050053664A1 (en) | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US8198328B2 (en) | 2004-01-21 | 2012-06-12 | New York University | Treatment of cancer using benzoic acid derivatives |
US20060210514A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin protection and moisturizing compositions and method of making the same |
WO2007025282A2 (en) * | 2005-08-24 | 2007-03-01 | Cedars-Sinai Medical Center | Use of fructose-based compounds for the diagnosis of cancer |
US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
US20090053137A1 (en) * | 2006-03-15 | 2009-02-26 | Moore Dennis A | Chelating Conjugates Having a Substituted Aromatic Moiety and Derivatives Thereof |
EP4251746A1 (de) | 2020-11-30 | 2023-10-04 | Cellectis SA | Verwendung von aminochinolinverbindungen zur höheren genintegration |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4584368A (en) * | 1978-10-13 | 1986-04-22 | Adolf W. Schwimmer | β-Glucuronidase activity and/or pH-dependent pharmaceuticals and thier methods of production |
US4337760A (en) * | 1978-10-13 | 1982-07-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
US4424348A (en) * | 1978-10-13 | 1984-01-03 | Adolf W. Schwimmer | Methods of manufacture of nitrile-containing glucuronic acid conjugates |
US4481195A (en) * | 1978-10-13 | 1984-11-06 | Adolf Schwimmer | Method for the treatment of tumors with β-glucuronidase activity dependent pharmaceuticals |
US5225542A (en) * | 1984-10-23 | 1993-07-06 | Max-Planck Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Specific carbohydrate-binding proteins (lectins) of mammalian tumor cells |
US5239062A (en) * | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
US5395924A (en) * | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
ATE94395T1 (de) * | 1986-05-09 | 1993-10-15 | Pulverer Gerhard | Verwendung von spezifischen monosacchariden zur herstellung eines arzneimittels zur verhinderung von metastasen maligner tumore. |
US4812590A (en) * | 1987-06-25 | 1989-03-14 | Merck & Co., Inc. | Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma |
CA2089375A1 (en) * | 1990-08-30 | 1992-03-01 | Tatsushi Toyokuni | Inhibition of metastatis potential and invasiveness by oligosaccharides or oligosaccharide antigens or antibodies |
MX9206309A (es) * | 1991-11-04 | 1994-05-31 | David Rubin | Metodo y composicion para tratar tumores que tienen alta actividad de tirosinasa. |
JPH05339148A (ja) * | 1992-05-28 | 1993-12-21 | T Knight Albert | 血液脳関門を通過する物質 |
-
1994
- 1994-12-21 US US08/360,352 patent/US5639737A/en not_active Expired - Fee Related
-
1995
- 1995-11-27 WO PCT/US1995/015097 patent/WO1996019243A1/en active IP Right Grant
- 1995-11-27 EP EP95940764A patent/EP0797453B1/de not_active Expired - Lifetime
- 1995-11-27 AT AT95940764T patent/ATE235257T1/de not_active IP Right Cessation
- 1995-11-27 AU AU42407/96A patent/AU692021B2/en not_active Ceased
- 1995-11-27 DE DE69530109T patent/DE69530109T2/de not_active Expired - Fee Related
- 1995-11-27 CA CA002208206A patent/CA2208206C/en not_active Expired - Fee Related
- 1995-12-20 IL IL116465A patent/IL116465A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
CA2208206A1 (en) | 1996-06-27 |
AU692021B2 (en) | 1998-05-28 |
IL116465A0 (en) | 1996-03-31 |
DE69530109T2 (de) | 2004-02-05 |
EP0797453A1 (de) | 1997-10-01 |
CA2208206C (en) | 2008-02-12 |
DE69530109D1 (de) | 2003-04-30 |
EP0797453B1 (de) | 2003-03-26 |
WO1996019243A1 (en) | 1996-06-27 |
IL116465A (en) | 2010-04-29 |
MX9704727A (es) | 1998-06-30 |
US5639737A (en) | 1997-06-17 |
AU4240796A (en) | 1996-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69530109D1 (de) | Zusammensetzung für behandlung von maligner tumore und ihre metastase | |
Laske et al. | Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice | |
Goff et al. | Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model | |
Shiah et al. | Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl) methacrylamide copolymer–doxorubicin/mesochlorin e6-OV-TL 16 antibody immunoconjugates | |
Maris et al. | Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program | |
TR200202231T2 (tr) | Amiloidojenik hastalığın önlenmesi ve tedavisi | |
DE69433818D1 (de) | Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung | |
ATE209908T1 (de) | RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN | |
EA200501810A1 (ru) | Композиция конъюгированного лекарственного средства | |
EP1434603A4 (de) | Behandlungsverfahren mit liganden-immunogenkonjugaten | |
BR9713197A (pt) | Meios para tratamento de hipertrofia de próstata e câncer de próstata | |
Ning et al. | Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system | |
TR200101174T2 (tr) | Migren tedavisi için 5HT1, reseptör agonistleri ve metoklopramid. | |
ES2173641T3 (es) | Composicion de derivados opiaceos para la fabricacion de medicamentos. | |
Kranjc et al. | Radiosensitising effect of electrochemotherapy with bleomycin in LPB sarcoma cells and tumors in mice | |
WO1999056723A3 (en) | Hemoglobine-haptoglobin complexes for targeted drug delivery | |
DE602004016376D1 (de) | Kombination von et-743 mit 5-fluorouracil pro-drugs zur behandlung von krebs | |
Pearson et al. | Chemoimmunotoxin therapy against a human colon tumor (HT-29) xenografted into nude mice | |
AR016427A1 (es) | CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE. | |
Philpott et al. | Improved selective cytotoxicity with an antibody-diphtheria toxin conjugate | |
Myklebust et al. | Targeted therapy with immunotoxins in a nude rat model for leptomeningeal growth of human small cell lung cancer | |
WO2001041747A3 (de) | Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs | |
Abbas et al. | Antibody‐Drug Conjugates Used in Breast Cancers | |
Epstein et al. | Use of the immunotoxin N901‐blocked ricin in patients with small‐cell lung cancer | |
Prados | Temozolomide in combination with other cytotoxic agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |